Publications

1. Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, Murray NR, Fields AP. Protein kinase Ciota mediates immunosuppression in lung adenocarcinoma. Sci Transl Med. 2022 Nov 16; 14 (671):eabq5931
   View PubMed
2. Inman KS, Liu Y, Scotti Buzhardt ML, Leitges M, Krishna M, Crawford HC, Fields AP, Murray NR. Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice. Cancers (Basel). 2022 Feb 4; 14 (3) Epub 2022 Feb 04
   View PubMed
3. Kenchappa RS, Liu Y, Argenziano MG, Banu MA, Mladek AC, West R, Luu A, Quinones-Hinojosa A, Hambardzumyan D, Justilien V, Leitges M, Sarkaria JN, Sims PA, Canoll P, Murray NR, Fields AP, Rosenfeld SS. Protein kinase C(iota) and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Rep. 2021 Nov 23; 37 (8):110054
   View PubMed
4. Liu Y, Justilien V, Fields AP, Murray NR. Recurrent copy number gains drive PKCiota expression and PKCiota-dependent oncogenic signaling in human cancers. Adv Biol Regul. 2020 Dec; 78:100754 Epub 2020 Sept 12
   View PubMed
5. Justilien V, Lewis KC, Meneses KM, Jamieson L, Murray NR, Fields AP. Protein kinase Ciota promotes UBF1-ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells. J Biol Chem. 2020 Jun 12; 295 (24):8214-8226 Epub 2020 Apr 29
   View PubMed
6. Liu Y, Yin N, Wang X, Khoor A, Sambandam V, Ghosh AB, Fields ZA, Murray NR, Justilien V, Fields AP. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. Cell Rep. 2020 Jan 21; 30 (3):771-782.e6
   View PubMed
7. Yin N, Liu Y, Murray NR, Fields AP. Oncogenic protein kinase Ciota signaling mechanisms in lung cancer: Implications for improved therapeutic strategies. Adv Biol Regul. 2020 Jan; 75:100656 Epub 2019 Sept 25
   View PubMed
8. Yin N, Liu Y, Khoor A, Wang X, Thompson EA, Leitges M, Justilien V, Weems C, Murray NR, Fields AP. Protein Kinase C? and Wnt/ß-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. Cancer Cell. 2019 Dec 09; 36(6):692-693.
   View PubMed
9. Justilien V, Lewis KC, Murray NR, Fields AP. Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC. Small GTPases. 2019 Sep; 10 (5):388-394 Epub 2017 July 05
   View PubMed
10. Yin N, Liu Y, Khoor A, Wang X, Thompson EA, Leitges M, Justilien V, Weems C, Murray NR, Fields AP. Protein Kinase C? and Wnt/ß-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. Cancer Cell. 2019 Aug 12; 36(2):156-167.e7. Epub 2019 Aug 01.
    View PubMed
11. Fields AP, Ali SA, Justilien V, Murray NR. Protein kinase Ciota: A versatile oncogene in the lung. Mol Cell Oncol. 2018; 5 (5):e1190886 Epub 2018 May 10
    View PubMed
12. Justilien V, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, Murray NR, Fields AP. Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. Cancer Cell. 2017 Feb 13; 31 (2):256-269 Epub 2017 Jan 19
    View PubMed
13. Wang Y, Justilien V, Brennan KI, Jamieson L, Murray NR, Fields AP. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene. 2017 Jan 26; 36 (4):534-545 Epub 2016 June 20
    View PubMed
14. Fields AP, Ali SA, Justilien V, Murray NR. Targeting oncogenic protein kinase Ciota for treatment of mutant KRAS LADC. Small GTPases. 2017 Jan 2; 8 (1):58-64 Epub 2016 May 31
    View PubMed
15. Murray NR, Justilien V, Fields AP. SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the Mouse. Cancer Cell 2016 Oct 10; 30 (4):505-507
    View PubMed
16. Fields AP, Ali SA, Murray NR. Oncogenic PKCiota decides tumor-initiating cell fate. Cell Cycle 2016 Sep 16; 15 (18):2383-4 Epub 2016 June 17
    View PubMed
17. Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP. Protein Kinase Ciota Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell. 2016 Mar 14; 29 (3):367-378
    View PubMed
18. Fields AP, Justilien V, Murray NR. The chromosome 3q26 OncCassette: A multigenic driver of human cancer. Adv Biol Regul. 2016 Jan; 60:47-63 Epub 2015 Dec 23
    View PubMed
19. Butler AM, Scotti Buzhardt ML, Erdogan E, Li S, Inman KS, Fields AP, Murray NR. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget. 2015 Jun 20; 6 (17):15297-310
    View PubMed
20. Liou GY, Doppler H, Braun UB, Panayiotou R, Scotti Buzhardt M, Radisky DC, Crawford HC, Fields AP, Murray NR, Wang QJ, Leitges M, Storz P. Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia. Nat Commun. 2015 Feb 20; 6:6200
    View PubMed
21. Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol. 2014 Aug 28; 20 (32):11160-81
    View PubMed
22. Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR, Fields AP. Protein kinase Calpha suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFbeta signaling axis. Oncogene. 2014 Apr 17; 33 (16):2134-44 Epub 2013 Apr 22
    View PubMed
23. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014 Feb 10; 25 (2):139-51
    View PubMed
24. Butler AM, Scotti Buzhardt ML, Li S, Smith KE, Fields AP, Murray NR. Protein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mechanism. PLoS One. 2013; 8 (8):e72061 Epub 2013 Aug 28
    View PubMed
25. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012 Sep 11; 22 (3):304-17
    View PubMed
26. Scotti ML, Smith KE, Butler AM, Calcagno SR, Crawford HC, Leitges M, Fields AP, Murray NR. Protein kinase C iota regulates pancreatic acinar-to-ductal metaplasia. PLoS One. 2012; 7 (2):e30509 Epub 2012 Feb 16
    View PubMed
27. Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One. 2012; 7 (4):e35040 Epub 2012 Apr 24
    View PubMed
28. Calcagno SR, Li S, Shahid MW, Wallace MB, Leitges M, Fields AP, Murray NR. Protein kinase C iota in the intestinal epithelium protects against dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2011 Aug; 17 (8):1685-97 Epub 2010 Nov 15
    View PubMed
29. Murray NR, Kalari KR, Fields AP. Protein kinase Ciota expression and oncogenic signaling mechanisms in cancer. J Cell Physiol. 2011 Apr; 226 (4):879-87
    View PubMed
30. Regala RP, Justilien V, Walsh MP, Weems C, Khoor A, Murray NR, Fields AP. Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation. PLoS One. 2011; 6 (10):e26439 Epub 2011 Oct 17
    View PubMed
31. Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res. 2010 Mar 1; 70 (5):2064-74 Epub 2010 Feb 23
    View PubMed
32. Fields AP, Calcagno SR, Krishna M, Rak S, Leitges M, Murray NR. Protein kinase Cbeta is an effective target for chemoprevention of colon cancer. Cancer Res. 2009 Feb 15; 69 (4):1643-50
    View PubMed
33. Murray NR, Weems J, Braun U, Leitges M, Fields AP. Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression. Cancer Res. 2009 Jan 15; 69 (2):656-62
    View PubMed
34. Su W, Necela BM, Fujiwara K, Kurakata S, Murray NR, Fields AP, Thompson EA. The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int J Cancer. 2008 Sep 1; 123 (5):991-7
    View PubMed
35. Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, Fields AP, Murray NR. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer. 2008 Jun 1; 122 (11):2462-70
    View PubMed
36. Fields AP, Murray NR. Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul. 2008; 48:166-78 Epub 2008 Mar 18
    View PubMed
37. Su W, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP, Thompson EA. Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics. 2007 Aug 20; 30 (3):342-53 Epub 2007 May 22
    View PubMed
38. Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res. 2006 Feb 1; 66: (3)1767-74.
    View PubMed
39. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem. 2004 Oct 29; 279 (44):45556-63 Epub 2004 Aug 20
    View PubMed
40. Murray NR, Jamieson L, Yu W, Zhang J, Gokmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, Fields AP. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol. 2004 Mar 15; 164 (6):797-802
    View PubMed
41. Yu W, Murray NR, Weems C, Chen L, Guo H, Ethridge R, Ceci JD, Evers BM, Thompson EA, Fields AP. Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J Biol Chem. 2003 Mar 28; 278(13):11167-74. Epub 2002 Dec 11.
    View PubMed
42. Fields AP, Murray NR, Gustafson WC. Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models. Methods Mol Biol. 2003; 233:539-53.
    View PubMed
43. Murray NR, Weems C, Chen L, Leon J, Yu W, Davidson LA, Jamieson L, Chapkin RS, Thompson EA, Fields AP. Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol. 2002 Jun 10; 157: (6)915-20.
    View PubMed
44. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res. 2001 Feb 15; 61(4):1375-81.
    View PubMed
45. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999 May 17; 145(4):699-711.
    View PubMed
46. Li Q, Subbulakshmi V, Fields AP, Murray NR, Cathcart MK. Protein kinase calpha regulates human monocyte O-2 production and low density lipoprotein lipid oxidation. J Biol Chem. 1999 Feb 5; 274(6):3764-71.
    View PubMed
47. Han Y, Meng T, Murray NR, Fields AP, Brasier AR. Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis. J Biol Chem. 1999 Jan 8; 274(2):939-47.
    View PubMed
48. Murray NR, Fields AP. Phosphatidylglycerol is a physiologic activator of nuclear protein kinase C. J Biol Chem. 1998 May 8; 273(19):11514-20.
    View PubMed
49. Murray NR, Fields AP. Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. J Biol Chem. 1997 Oct 31; 272(44):27521-4.
    View PubMed
50. Sun B, Murray NR, Fields AP. A role for nuclear phosphatidylinositol-specific phospholipase C in the G2/M phase transition. J Biol Chem. 1997 Oct 17; 272(42):26313-7.
    View PubMed
51. Ritke MK, Murray NR, Allan WP, Fields AP, Yalowich JC. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. Mol Pharmacol. 1995 Nov; 48(5):798-805.
    View PubMed
52. Walker SD, Murray NR, Burns DJ, Fields AP. Protein kinase C chimeras: catalytic domains of alpha and beta II protein kinase C contain determinants for isotype-specific function. Proc Natl Acad Sci U S A. 1995 Sep 26; 92(20):9156-60.
    View PubMed
53. Huntley CC, De BP, Murray NR, Fields AP, Banerjee AK. Human parainfluenza virus type 3 phosphoprotein: identification of serine 333 as the major site for PKC zeta phosphorylation. Virology. 1995 Aug 20; 211(2):561-7.
    View PubMed
54. Murray NR, Burns DJ, Fields AP. Presence of a beta II protein kinase C-selective nuclear membrane activation factor in human leukemia cells. J Biol Chem. 1994 Aug 19; 269(33):21385-90.
    View PubMed
55. Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation. J Biol Chem. 1993 Jul 25; 268(21):15847-53.
    View PubMed
56. Deeg MA, Murray NR, Rosenberry TL. Identification of glycoinositol phospholipids in rat liver by reductive radiomethylation of amines but not in H4IIE hepatoma cells or isolated hepatocytes by biosynthetic labeling with glucosamine. J Biol Chem. 1992; 267:18581-8.
    View PubMed
57. Toutant JP, Roberts WL, Murray NR, Rosenberry TL. Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and serum phospholipase D. Eur J Biochem. 1989 Apr 1; 180(3):503-8.
    View PubMed